{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-025929","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2022-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.501563+00:00","generated_at":"2026-06-23T09:21:09.881214+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palisade Bio cuts workforce by 20% and identifies over $1.5M in annual cost savings to focus on LB1148","bullets":["Reduction in force of 20% with estimated cash severance of $380,148.","Anticipates annual cost savings of ~$773,000 from workforce reduction plus up to $800,000 from other cuts, totaling >$1.5M.","Company to focus all resources on advancing lead asset LB1148, with Phase 3 enrollment targeted within 18-24 months.","Payment of severance expected to be substantially completed by end of Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-025929","json":"https://secwatch.observer/filing/0001493152-22-025929.json","markdown":"https://secwatch.observer/filing/0001493152-22-025929.md","text":"https://secwatch.observer/filing/0001493152-22-025929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/0001493152-22-025929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:21:09.881214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}